COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE NEOADJUVANT TREATMENT OF HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN CHINA

被引：0
|
作者：
Li, H. [1 ]
Guan, X. [1 ]
Chen, Q. [2 ]
Hao, C. [3 ]
Li, J. [4 ]
Wang, Y. [5 ]
Zhang, J. [4 ]
Li, K. [1 ]
Liu, C. [6 ]
Chu, Y. [7 ]
Ma, A. [1 ]
机构：
[1] China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China
[2] Guangdong Tradit Chinese Med Hosp, Guangzhou, Guangdong, Peoples R China
[3] Tianjin Med Univ Canc Hosp, Tianjin, Peoples R China
[4] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Shandong Canc Hosp, Jinan, Shandong, Peoples R China
[6] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
[7] Shanghai Roche Pharmaceut Ltd, Beijing 11, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN230
引用
收藏
页码：S480 / S480
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
    Garrison, Louis P., Jr.
    Babigumira, Joseph
    Tournier, Clement
    Goertz, Hans-Peter
    Lubinga, Solomon J.
    Perez, Edith A.
    [J]. VALUE IN HEALTH, 2019, 22 (04) : 408 - 415
  • [2] COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA
    Guan, X.
    Li, H.
    Chen, Q.
    Hao, C.
    Li, J.
    Wang, Y.
    Zhang, J.
    Xu, H.
    Liu, C.
    Chu, Y.
    Ma, A.
    [J]. VALUE IN HEALTH, 2019, 22 : S405 - S406
  • [3] Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada
    Attard, C. L.
    Pepper, A. N.
    Brown, S. T.
    Thompson, M. F.
    Thuresson, P. -O.
    Yunger, S.
    Dent, S.
    Paterson, A. H.
    Wells, G. A.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 173 - 188
  • [4] Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer.
    Babigumira, Joseph B.
    Santos, Eduardo
    Antao, Vincent Percival
    Wang, Bruce
    Portera, Chia C.
    Kamath, Tripthi
    Garrison, Louis P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States (vol 22, pg 408, 2019)
    Minckwitz, Von
    [J]. VALUE IN HEALTH, 2019, 22 (07) : 843 - 843
  • [6] BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
    Dang, Chau
    Ewer, Michael S.
    Delaloge, Suzette
    Ferrero, Jean-Marc
    Colomer, Ramon
    de la Cruz-Merino, Luis
    Werner, Theresa L.
    Dadswell, Katherine
    Verrill, Mark
    Eiger, Daniel
    Sarkar, Sriparna
    de Haas, Sanne Lysbet
    Restuccia, Eleonora
    Swain, Sandra M.
    [J]. CANCERS, 2022, 14 (11)
  • [7] Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer
    Konishi, Takaaki
    Fujiogi, Michimasa
    Michihata, Nobuaki
    Ohbe, Hiroyuki
    Matsui, Hiroki
    Fushimi, Kiyohide
    Tanabe, Masahiko
    Seto, Yasuyuki
    Yasunaga, Hideo
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1115 - 1123
  • [8] Cost-effectiveness of adjuvant chemotherapy plus trastuzumab (T) in HER2-positive breast cancer
    Liberato, N. L.
    Marchetti, M.
    Barosi, G.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI6 - XI6
  • [9] Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report
    Yamashita, Yuji
    Tanaka, Yuko
    Kono, Seishi
    Nishimura, Meiko
    Mukohara, Toru
    Morinaga, Yukiko
    Hara, Shigeo
    Takao, Shintaro
    [J]. BREAST CARE, 2017, 12 (01) : 45 - 47
  • [10] Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China
    Wang, Hao
    Wang, Ye
    Gong, Ruixue
    Geng, Yuyu
    Li, Li
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11382 - 11393
12345